391-P: Individualized Optimization of Duration and Threshold of Sensor Hypoglycemia Improves Identification of Symptomatic Hypoglycemia Episodes—Hypo-METRICS Study
Authors: MAHMOUDI ZEINAB , DIVILLY PATRICK , MARTINE-EDITH GILBERTE , BOIROUX DIMITRI , ZAREMBA NATALIE , SOEHOLM UFFE , GOMES MIKEL , VAAG ALLAN A. , SPEIGHT JANE , DE GALAN BASTIAAN E. , PEDERSEN-BJERGAARD ULRIK , MCCRIMMON RORY J. , RENARD ERIC , HELLER SIMON R. , EVANS MARK , MADER JULIA K. , AMIEL STEPHANIE A. , CHOUDHARY PRATIK ,   HYPO-RESOLVE CONSORTIUM
Published: June 2023

Current definitions of sensor detected hypoglycemia (SDH) give high levels of asymptomatic hypoglycemia on continuous glucose monitoring (CGM). We defined individually optimised thresholds and durations for sensor detected hypoglycemia (SDH) that better identify symptomatic hypoglycemia experienced by people with insulin treated diabetes. We analysed 10 weeks of blinded CGM (Libre 2) and FitBit data from 435 participants [217 type 1, 218 type 2]. They self reported symptomatic hypoglycemia on the Hypo-METRICS smartphone app. We used particle Markov chain Monte Carlo optimization to generate the threshold and duration of SDH that maximizes detection of symptomatic hypoglycemia for each individual (and by Fitbit sleep status). When using individual definitions of SDH, precision for detection of symptomatic hypoglycemia increased by 23% with 2% loss of sensitivity vs the consensus definition of Level 1 SDH (70mg/dl &gt; 15 mins). Precision and sensitivity increased by 41% and 20% respectively vs level 2 SDH (54 mg/dl &gt; 15 mins). Increased precision, with minimal change of sensitivity, were greatest during sleep, and irrespective of diabetes types and sleep status (Table). Optimizing SDH definitions at the individual level and by sleep status could minimize false alarms without increasing missed clinically important hypoglycemia episodes.

Disclosure
Z.Mahmoudi: Employee; Novo Nordisk. B.E.De galan: Research Support; Novo Nordisk. U.Pedersen-bjergaard: Advisory Panel; Novo Nordisk A/S, Sanofi, Vertex Pharmaceuticals Incorporated. R.J.Mccrimmon: Advisory Panel; Sanofi, Speaker's Bureau; Novo Nordisk A/S. E.Renard: Consultant; Abbott Diabetes, Dexcom, Inc., AstraZeneca, Boehringer-Ingelheim, Eli Lilly and Company, Insulet Corporation, MannKind Corporation, Novo Nordisk, Sanofi, Roche Diabetes Care. S.R.Heller: Advisory Panel; Zealand Pharma A/S, Zucara Therapeutics, Other Relationship; Eli Lilly and Company, Research Support; Dexcom, Inc., Speaker's Bureau; Novo Nordisk, Medtronic. M.Evans: Advisory Panel; Zucara Therapeutics, Pila Pharma, Dexcom, Inc., Other Relationship; Novo Nordisk, AstraZeneca, Abbott Diabetes, Speaker's Bureau; Eli Lilly and Company. J.K.Mader: Advisory Panel; Novo Nordisk A/S, Abbott Diabetes, Roche Diabetes Care, Eli Lilly and Company, Sanofi, Medtronic, Becton, Dickinson and Company, Pharmasense, embecta, Research Support; A. Menarini Diagnostics, Abbott Diabetes, Roche Diabetes Care, Dexcom, Inc., Profusa, Inc., Speaker's Bureau; Novo Nordisk A/S, A. Menarini Diagnostics, Abbott Diabetes, Roche Diabetes Care, Eli Lilly and Company, Sanofi, Boehringer Ingelheim Inc., Becton, Dickinson and Company, Ypsomed AG, Viatris Inc., Servier Laboratories, Medtrust, Stock/Shareholder; Decide Clinical Software GmbH. S.A.Amiel: Advisory Panel; Medtronic, Other Relationship; Sanofi, Novo Nordisk. P.Choudhary: Advisory Panel; Medtronic, Novo Nordisk, Dexcom, Inc., MannKind Corporation, Insulet Corporation, Research Support; Abbott Diabetes, Speaker's Bureau; Sanofi, Lilly. Hypo-resolve consortium: n/a. P.Divilly: None. G.Martine-edith: Other Relationship; Novo Nordisk A/S. D.Boiroux: Employee; Novo Nordisk A/S. N.Zaremba: None. U.Soeholm: Employee; Novo Nordisk A/S. M.Gomes: Employee; Novo Nordisk A/S. A.A.Vaag: None. J.Speight: Research Support; Sanofi, Medtronic, Abbott Diabetes, Lilly, Novo Nordisk A/S, Speaker's Bureau; Sanofi.

Funding
Innovative Medicines Initiative 2 Joint Undertaking (777460)